Skip to main content
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Special Issues
Supplements
Categories
Conference Correspondent
ASH 2023 - CLL
SABCS 2023 - HR+/HER2- MBC
Web Exclusives
All Web Exclusives
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Gastrointestinal Cancer Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Policy
Advertise
ASCO Highlights
Meeting Highlights
ASCO Highlights
Efficacy and Safety of Entrectinib in Patients with NTRK Fusion–Positive Solid Tumors
Read More
Meeting Highlights
ASCO Highlights
Next-Generation RET Inhibitor TPX-0046 Is Active in Drug-Resistant and Naïve RET-Driven Cancer Models
Read More
Meeting Highlights
ASCO Highlights
Antitumor Activity of Selpercatinib (LOXO-292) in Patients with RET-Mutant Medullary Thyroid Cancer
Read More
Meeting Highlights
ASCO Highlights
Liquid Biopsy Compared with Tissue Biopsy for Molecular Profiling in Patients with NSCLC
Read More
Meeting Highlights
ASCO Highlights
Efficacy of Amivantamab (JNJ-61186372) in Patients with NSCLC Harboring EGFR Exon 20 Insertion Mutation
Read More
Meeting Highlights
ASCO Highlights
Barriers to Targeted Therapies for NSCLC Patients with Highly Actionable Gene Variants in the Veterans Health Affairs Program
Read More
Meeting Highlights
ASCO Highlights
Impact of Immune-Related Adverse Events on Checkpoint Inhibitor Consolidation Therapy in Stage III NSCLC
Read More
Meeting Highlights
ASCO Highlights
Patterns of Acquired Resistance in Patients with NSCLC Who Receive PD-1 Inhibitors
Read More
Meeting Highlights
ASCO Highlights
Characteristics of Patients Who Achieve Long-Term Response with PD-1 Blockade
Read More
Meeting Highlights
ASCO Highlights
Smoking Cessation and Lung Cancer: Recent Quitters Benefit Too
Read More
1
2
3
4
5
Page 3 of 5
Results 21 - 30 of 42